John has over 40 years in the pharmaceutical industry, including 29 years at GSK R&D, where he served as SVP of Platform Technology and Science, overseeing 40% of R&D staff. He led teams developing small molecules, biopharmaceuticals, and cell and gene therapies from discovery through commercialization. In 2017, John established GSK’s first AI-driven drug discovery unit and subsequently served as CTO for an AI-enabled drug discovery startup.
Currently, John is CEO of ATOM Research Alliance (ARA), a nonprofit advancing AI and ML to expedite drug discovery for public benefit. He also consults for companies in drug discovery and diagnostics. A pioneer in healthcare AI, John founded the ATOM consortium and was the first Chair of the Executive Committee for the Alliance for Artificial Intelligence in Healthcare. He holds a PhD in biological chemistry from Penn State University.